1. Scrip
  2. >>R&D

On Deck For Alnylam: Three Phase III Starts In 2025

 
• By Jessica Merrill

The RNAi specialist outlined plans to initiate three Phase III trials this year – two for nucresiran in ATTR amyloidosis and one for zilebesiran for hypertension – during an R&D day in New York.

(Shutterstock)
Key Takeaways

Alnylam showcased its RNAi pipeline during a four-hour R&D day in New York.

A big focus was the next-generation TTR silencer nucresiran and the hepatic angiotensinogen synthesis inhibitor zilebesiran for hypertension, both of which are moving into Phase III.

Further out, management highlighted Phase I assets in neuroscience, including mivelsiran for Alzheimer’s disease and ALN-HTT02 for Huntington’s disease.

The big milestone for Alnylam this year is the expected US Food and Drug Administration approval of Amvuttra (vutrisiran) for an expanded indication in patients with ATTR amyloidosis with cardiomyopathy...

“There’s so much more opportunity ahead of us as we look forward to fulfill the promise of RNAi and usher in the next era of growth for the company,” CEO...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from R&D

Summit’s Ivonescimab Shows Significance On PFS, But Not Overall Survival

 
• By Joseph Haas

In a study intended to show similar benefit in western patients, PD-1/VEGF-targeting ivonescimab met a progression-free survival endpoint, but missed on OS.

Sanofi Bid For Second COPD Approval Hurt By Mixed Itepekimab Data

 
• By Kevin Grogan

One Phase III trial hits but a second study misses by a mile.

In Brief: Neurocrine Details New Data For Schizophrenia Drug Moving To Phase III

 
• By Sushmita Panda

Neurocrine reports new details of positive Phase II results in schizophrenia and a favorable safety and cardiovascular profile for its first-in-class oral M4 agonist, now moving to Phase III trials.

Merck & Co./Daiichi Pull Patritumab Deruxtecan BLA On Disappointing OS

 
• By Jessica Merrill

Patritumab deruxtecan is the lead antibody drug conjugate in a $22bn deal signed between the two partners, with the decision marking a disappointing setback

More from Advanced Therapies

Zelluna Believes Its TCR Tech Can Unlock Natural Killer Cell Potential

 
• By Andrew McConaghie

While CAR-NKs have pivoted towards autoimmune disease, the Norwegian biotech believes its unique platform can deliver in oncology

Abeona Sets $3.1m Price For Rare Skin Disorder Gene Therapy

 
• By Joseph Haas

Abeona plans to offer an outcomes-based payment model for Zevaskyn, which likely will see complementary use with Krystal’s Vyjuvek in recessive dystrophic epidermolysis bullosa patients.

Gilead Pipeline Progress Offsets Oncology Sales Slowdown

 
• By Alaric DeArment

Sales of the company’s approved cancer therapies were weaker or down, but Trodelvy is likely to see a label expansion and cell therapies are making progress.